A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial | Nature Medicine
A single intravenous dose of the psychedelic dimethyltryptamine, combined with psychological support, produces rapid and lasting reductions in depressive symptoms in adults with major depressive disorder.
Download PDF Subjects Depression Trauma Abstract Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD. Participants r
related reading
- The serotonin theory of depression: a systematic umbrella review of the evidencenature.com
- Case Study: The Clinical Translation of Transcranial Magnetic Stimulationmilan.cvitkovic.net
- A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a depubmed.ncbi.nlm.nih.gov
- Psychedelics reopen the social reward learning critical periodirp.cdn-website.com
- Everything you need to know about psychedelics and mental illnessstuartritchie.substack.com
- Closed-loop neuromodulation in an individual with treatment-resistant depression | Nature Medicinenature.com
- Treatment-resistant depression - Wikipediaen.wikipedia.org
- Mindbloom: ketamine therapy for anxiety and depressionmindbloom.com
- The Degradation Drug - The American Scholartheamericanscholar.org
- How to have a safe psychedelic trippsyche.co
- An international mega-analysis of psychedelic drug effects on brain circuit function | Nature Medicinenature.com
- Pyramidal cell types and 5-HT2A receptors are essential for psilocybin’s lasting drug action | bioRxivbiorxiv.org